Mylan secures victory in another EpiPen case
A federal Kansas judge has dismissed a pharmacy operator’s putative class action accusing Mylan and Pfizer of illegally monopolising the market for epinephrine auto-injectors used to treat severe allergic reactions.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10